Sort   by:  
 Page size 
ProteomicsMitoxantrone impacts on proteoform abundance in HR proficient and deficient ovarian cancer cells
Mitoxantrone (MX) is regularly used to treat several cancers, yet despite its long history in the clinic, recent studies continue to unveil novel protein targets that may contribute to the cytotoxic effects of the drug, as well as potential non-canonical antitumor activity. A better understanding of...
ORGANISM(S): Homo sapiens (Human) 
2025-12-01 | PXD069401 | Pride
Ovarian cancer Mitoxantrone 
TranscriptomicsRNA microarray of human cervical cancer cell line HeLa treated with imatinib, mitoxantrone or mitoxantrone+imatinib combination against untreated controls
Critical DNA repair pathways become deranged during cancer development. This vulnerability may be exploited with DNA-targeting chemotherapy. Topoisomerase II inhibitors induce double-strand breaks which are detrimental to the cell, if not repaired. This repair process requires high-fidelity function...
ORGANISM(S): Homo sapiens 
2021-09-22 | E-MTAB-9475 | biostudies-arrayexpress
ProteomicsSurveying the proteome-wide landscape of Mitoxantrone and examining drug-sensitivity in BRCA1-deficient ovarian cancer using quantitative proteomics
Mitoxantrone (MX) is regularly used to treat several cancers, yet despite its long history in the clinic, recent studies continue to unveil novel protein targets that may contribute to the cytotoxic effects of the drug, as well as potential non-canonical antitumor activity. A better understanding of...
ORGANISM(S): Homo sapiens (Human) 
2025-12-01 | PXD069034 | Pride
Human Mitoxantrone Ovarian cancer 
TranscriptomicsRNA-seq for siPRKDC and siControl in human HL-60/MX2 mitoxantrone resistant derivative of the HL-60 cell line
Anthracyclines, topoisomerase 2 enzyme poison that results in DNA damage, are currently used in acute myeloid leukemia (AML) treatment. Identifying the mechanisms underlying drug resistance remains an important question. Here, using a mitoxantrone-resistant cell line (HL-60/MX2), we found upregulati...
ORGANISM(S): Homo sapiens 
2025-12-31 | E-MTAB-13769 | biostudies-arrayexpress
TranscriptomicsPrediction of drug sensitivity
Tumor cell lines and drug-resistant counterparts. These data support the publication Gyorffy et al, Oncogene 2005 (July), Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. We contrasted the express...
ORGANISM(S): Homo sapiens 
2005-07-30 | E-GEOD-3034 | biostudies-arrayexpress
GenomicsMitoxantrone-liposome sensitizes Flt3-ITD acute myeloid leukemia to gilteritinib treatment
Mitoxantrone-liposome sensitizes Flt3-ITD acute myeloid leukemia to gilteritinib treatment
PRJNA1156893 | ENA
GenomicsRNA functional modulation by Mitoxantrone via RNA structural ensemble repartitioning
RNA functional modulation by Mitoxantrone via RNA structural ensemble repartitioning
PRJNA1291096 | ENA
TranscriptomicsMolecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy
Patients with high-risk localized prostate cancer (tumor-node-metastasis ≥ T2b or prostate-specific antigen ≥ 15 ng/mL or Gleason glade ≥ 4+3) were enrolled into a phase II clinical trial of neoadjuvant chemotherapy with docetaxel and mitoxantrone followed by prostatectomy. Pretreatment prostate tis...
ORGANISM(S): Homo sapiens 
2012-08-29 | E-GEOD-40434 | biostudies-arrayexpress
UnknownAsymmetric enzymatic glycosylation of mitoxantrone.
Not available
S-EPMC3099400 | biostudies-literature
GenomicsTo investigate the effects of NRF2 inhibitors (pyrimethamine and mitoxantrone) on gene expression in a human esophageal squamous cell carcinoma cell line (KYSE70)
To investigate the effects of NRF2 inhibitors (pyrimethamine and mitoxantrone) on gene expression in a human esophageal squamous cell carcinoma cell line (KYSE70)
PRJNA724017 | ENA
Sort   by:  
 Page size